• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第二代嵌合抗原受体信号转导结构域调控 CAR 信号输入效率

Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.

机构信息

Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.

出版信息

Int J Mol Sci. 2021 Mar 1;22(5):2476. doi: 10.3390/ijms22052476.

DOI:10.3390/ijms22052476
PMID:33804441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7957710/
Abstract

T cells that are genetically engineered to express chimeric antigen receptor (CAR) have a strong potential to eliminate tumor cells, yet the CAR-T cells may also induce severe side effects due to an excessive immune response. Although optimization of the CAR structure is expected to improve the efficacy and toxicity of CAR-T cells, the relationship between CAR structure and CAR-T cell functions remains unclear. Here, we constructed second-generation CARs incorporating a signal transduction domain (STD) derived from CD3ζ and a 2nd STD derived from CD28, CD278, CD27, CD134, or CD137, and investigated the impact of the STD structure and signaling on CAR-T cell functions. Cytokine secretion of CAR-T cells was enhanced by 2nd STD signaling. T cells expressing CAR with CD278-STD or CD137-STD proliferated in an antigen-independent manner by their STD tonic signaling. CAR-T cells incorporating CD28-STD or CD278-STD between TMD and CD3ζ-STD showed higher cytotoxicity than first-generation CAR or second-generation CARs with other 2nd STDs. The potent cytotoxicity of these CAR-T cells was not affected by inhibiting the 2nd STD signals, but was eliminated by placing the STDs after the CD3ζ-STD. Our data highlighted that CAR activity was affected by STD structure as well as by 2nd STD signaling.

摘要

经基因工程改造表达嵌合抗原受体 (CAR) 的 T 细胞具有强大的消除肿瘤细胞的潜力,但由于过度的免疫反应,CAR-T 细胞也可能引起严重的副作用。虽然优化 CAR 结构有望提高 CAR-T 细胞的疗效和毒性,但 CAR 结构与 CAR-T 细胞功能之间的关系尚不清楚。在这里,我们构建了第二代 CAR,其中包含源自 CD3ζ 的信号转导结构域 (STD) 和源自 CD28、CD278、CD27、CD134 或 CD137 的第二个 STD,并研究了 STD 结构和信号对 CAR-T 细胞功能的影响。第二信号转导结构域的信号增强了 CAR-T 细胞的细胞因子分泌。通过其 STD 持续信号,表达带有 CD278-STD 或 CD137-STD 的 CAR 的 T 细胞以抗原非依赖性方式增殖。在跨膜结构域 (TMD) 和 CD3ζ-STD 之间包含 CD28-STD 或 CD278-STD 的 CAR-T 细胞比第一代 CAR 或具有其他第二信号转导结构域的第二代 CAR 显示出更高的细胞毒性。这些 CAR-T 细胞的强大细胞毒性不受抑制第二信号转导结构域信号的影响,但通过将信号转导结构域放置在 CD3ζ-STD 之后而被消除。我们的数据强调了 CAR 活性受 STD 结构以及第二信号转导结构域信号的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/8dd094e90bdd/ijms-22-02476-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/6c3f0ace8eb4/ijms-22-02476-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/284e7b77ca5b/ijms-22-02476-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/1699815cb06f/ijms-22-02476-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/65409dc7d3fd/ijms-22-02476-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/8dd094e90bdd/ijms-22-02476-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/6c3f0ace8eb4/ijms-22-02476-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/284e7b77ca5b/ijms-22-02476-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/1699815cb06f/ijms-22-02476-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/65409dc7d3fd/ijms-22-02476-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baeb/7957710/8dd094e90bdd/ijms-22-02476-g005.jpg

相似文献

1
Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.第二代嵌合抗原受体信号转导结构域调控 CAR 信号输入效率
Int J Mol Sci. 2021 Mar 1;22(5):2476. doi: 10.3390/ijms22052476.
2
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.嵌合抗原受体的铰链和跨膜结构域调节受体表达和信号转导阈值。
Cells. 2020 May 9;9(5):1182. doi: 10.3390/cells9051182.
3
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2 Generation Chimeric Antigen Receptor-Modified T Cells.4-1BB 信号增强了嵌合抗原受体修饰的 CD28 整合第二代 T 细胞的抗肿瘤活性。
Front Immunol. 2020 Nov 13;11:539654. doi: 10.3389/fimmu.2020.539654. eCollection 2020.
4
Chimeric Antigen Receptor T Cell Bearing Herpes Virus Entry Mediator Co-Stimulatory Signal Domain Exhibits Exhaustion-Resistant Properties.嵌合抗原受体 T 细胞携带疱疹病毒进入介质共刺激信号域,表现出抗衰竭特性。
Int J Mol Sci. 2024 Aug 8;25(16):8662. doi: 10.3390/ijms25168662.
5
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.嵌合抗原受体 T 细胞共转导 CD28 和 4-1BB 基因在 B 细胞白血病患者体内的扩增与抗肿瘤活性。
Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2.
6
Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.工程化 CD28ζ CAR 的细胞质信号传导以改善治疗功能。
Front Immunol. 2020 Jun 19;11:1046. doi: 10.3389/fimmu.2020.01046. eCollection 2020.
7
Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.嵌合抗原受体 T 细胞过继转移 IL13Rα2 特异性受体可在胶质母细胞瘤中创造促炎环境。
Mol Ther. 2018 Apr 4;26(4):986-995. doi: 10.1016/j.ymthe.2018.02.001. Epub 2018 Feb 8.
8
Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.采用表达嵌合型程序性死亡受体1(chimeric-PD1)-接头蛋白10(Dap10)受体的小鼠T细胞进行过继性转移作为淋巴瘤的免疫疗法。
Immunology. 2017 Nov;152(3):472-483. doi: 10.1111/imm.12784. Epub 2017 Jul 27.
9
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
10
Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.采用慢病毒载体表达合成 PD1/CD28 融合受体的基因工程 CLDN18.2 CAR-T 细胞。
J Microbiol. 2024 Jul;62(7):555-568. doi: 10.1007/s12275-024-00133-0. Epub 2024 May 3.

引用本文的文献

1
Direct visualization of chimeric antigen receptors on primary human T cells using STORM super-resolution microscopy.使用STORM超分辨率显微镜对原代人T细胞上的嵌合抗原受体进行直接可视化。
Front Immunol. 2025 Aug 1;16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.
2
Targets for CAR Therapy in Multiple Myeloma.多发性骨髓瘤中CAR疗法的靶点
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.
3
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.嵌合抗原受体T细胞(CAR-T)疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战

本文引用的文献

1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.癌症免疫治疗学会(SITC)免疫效应细胞相关不良事件临床实践指南。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001511.
2
Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold.嵌合抗原受体的铰链和跨膜结构域调节受体表达和信号转导阈值。
Cells. 2020 May 9;9(5):1182. doi: 10.3390/cells9051182.
3
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
4
Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.影响新型抗 HIV 嵌合抗原受体(CAR)构建体表面 CD4 表达的细胞外结构域、铰链和跨膜决定因素。
PLoS One. 2024 Aug 12;19(8):e0293990. doi: 10.1371/journal.pone.0293990. eCollection 2024.
5
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.利用单细胞测序技术研究 CAR-T 细胞和白血病/淋巴瘤的转录特征。
Int J Mol Sci. 2024 Feb 19;25(4):2416. doi: 10.3390/ijms25042416.
6
Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.影响新型抗HIV嵌合抗原受体(CAR)构建体表面CD4表达的细胞外结构域、铰链区和跨膜决定因素。
bioRxiv. 2023 Oct 26:2023.10.25.563930. doi: 10.1101/2023.10.25.563930.
7
Emerging Immunotherapy Approaches for Treating Prostate Cancer.新兴的免疫疗法在前列腺癌治疗中的应用。
Int J Mol Sci. 2023 Sep 20;24(18):14347. doi: 10.3390/ijms241814347.
8
Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors-A Narrative Review.辐射剂量与嵌合抗原受体T细胞的调控:实体瘤中一种有前景的新武器——综述
J Pers Med. 2023 Aug 14;13(8):1261. doi: 10.3390/jpm13081261.
9
Combination of CAR‑T cell therapy and radiotherapy: Opportunities and challenges in solid tumors (Review).嵌合抗原受体T细胞疗法与放射疗法的联合:实体瘤治疗中的机遇与挑战(综述)
Oncol Lett. 2023 May 16;26(1):281. doi: 10.3892/ol.2023.13867. eCollection 2023 Jul.
10
Scoring model based on the signature of non-m6A-related neoantigen-coding lncRNAs assists in immune microenvironment analysis and TCR-neoantigen pair selection in gliomas.基于非 m6A 相关新抗原编码 lncRNA 特征的评分模型可辅助胶质瘤免疫微环境分析和 TCR-新抗原对选择。
J Transl Med. 2022 Oct 29;20(1):494. doi: 10.1186/s12967-022-03713-z.
THEMIS-SHP1 通过 4-1BB 招募调控嵌合抗原受体重定向 T 细胞的 LCK 介导的启动。
Cancer Cell. 2020 Feb 10;37(2):216-225.e6. doi: 10.1016/j.ccell.2019.12.014. Epub 2020 Jan 30.
4
Engineering strategies to overcome the current roadblocks in CAR T cell therapy.克服 CAR T 细胞疗法当前障碍的工程策略。
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167. doi: 10.1038/s41571-019-0297-y. Epub 2019 Dec 17.
5
Analysis of CAR-Mediated Tonic Signaling.嵌合抗原受体(CAR)介导的张力信号分析。
Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17.
6
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.4-1BB或CD28共刺激的靶向CD19的CAR-T细胞治疗B细胞非霍奇金淋巴瘤的平行比较
Mol Ther Oncolytics. 2019 Aug 28;15:60-68. doi: 10.1016/j.omto.2019.08.002. eCollection 2019 Dec 20.
7
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.选择嵌合抗原受体的共刺激结构域:功能及临床考量
Clin Transl Immunology. 2019 May 11;8(5):e1049. doi: 10.1002/cti2.1049. eCollection 2019.
8
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.嵌合抗原受体在癌症治疗设计中的局限性。
Cells. 2019 May 17;8(5):472. doi: 10.3390/cells8050472.
9
Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.CAR 激活电位的校准指导 T 细胞的替代命运和治疗效力。
Nat Med. 2019 Jan;25(1):82-88. doi: 10.1038/s41591-018-0290-5. Epub 2018 Dec 17.
10
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.拓展 CAR T 细胞疗法在实体瘤中的治疗窗口:CAR T 细胞生物学的已知与未知。
Front Immunol. 2018 Oct 26;9:2486. doi: 10.3389/fimmu.2018.02486. eCollection 2018.